Other Deal Trends 2026: Activity Surges 1271% in 6 Months

96 deals in six months — up from 7 in the prior period. That's a 1271% increase in deal activity categorized under "other" modalities between the trailing half (August 2025 – February 2026) and the current half (February 2026 – August 2026). This isn't noise. The data shows that Big Pharma BD teams are aggressively pursuing assets outside traditional small molecule, antibody, and cell therapy categories — and they're paying top dollar to do it.

The surge reflects a structural reallocation of pipeline capital toward platform technologies, novel biologics hybrids, gene editing delivery systems, radiopharmaceuticals, and mechanism-agnostic modalities that don't fit neatly into legacy classification buckets. When CSPC Pharmaceutical commands an $18.5B total deal value from AstraZeneca, the signal is unmistakable: other licensing 2026 is where the boldest bets are being placed.

The Data — Other Deal Activity, Period over Period

A jump from single digits to nearly triple digits in one six-month window demands scrutiny. This isn't gradual adoption. It's a phase transition. The prior period's 7 deals likely represented exploratory transactions — option deals, small research collaborations, early-stage platform licenses. The current period's 96 deals include multiple nine- and ten-figure commitments from the world's largest acquirers. The category has moved from R&D curiosity to strategic imperative.

What's Driving the Trend

Pipeline exhaustion in traditional modalities is the primary catalyst. The antibody space is saturated. ADC deal pricing has normalized after the 2023–2025 frenzy. Cell therapy manufacturing economics remain punishing outside of hematological oncology. Pharma BD teams are being forced to look beyond their comfort zones, and CFOs are signing off because the competitive math demands it. If your pipeline is 70% monoclonal antibodies in 2026, your board has questions.

Regulatory tailwinds are accelerating this shift. The FDA's evolving framework for platform technologies, combination modalities, and AI-designed therapeutics has reduced development risk for novel asset classes. The agency's increasing willingness to grant breakthrough and accelerated designations to unconventional modalities — particularly in rare disease and immunology — has shortened the expected time-to-market for assets that would have languished in regulatory uncertainty three years ago. This de-risks the deals from the buyer's perspective and inflates valuation expectations from the seller's side.

Capital availability is also a factor, but a secondary one. The real driver is strategic desperation. Patent cliffs hitting between 2026 and 2030 — representing over $200B in at-risk revenue across the top 20 pharma companies — are forcing aggressive external innovation sourcing. When your LOE exposure is that severe, you don't have the luxury of waiting for a modality to mature. You buy early, you buy often, and you buy across categories. That's exactly what we're seeing in the other deal trends 2026 data. Review how these valuations compare against historical norms using our Deal Benchmarks dashboard.

Notable Deals

The CSPC-AstraZeneca deal is the headline. A $1.2B upfront payment with a total deal value of $18.5B is the kind of transaction that redefines a category. AstraZeneca is not hedging — this is a conviction bet on CSPC's portfolio, likely spanning multiple non-traditional modalities. The fact that two separate CSPC-AstraZeneca transactions appear within three days (July 12 and July 15) suggests a multi-asset or platform-level deal structure, possibly with separate economics for different territorial or indication rights. This is a masterclass in deal architecture from AstraZeneca's BD team.

Omeros securing a $2.4B TDV from Novo Nordisk is equally significant. Omeros has long operated in the complement and GPCR space with assets that defy easy modality classification. Novo Nordisk's willingness to pay at this level — for a company with a market cap that has historically traded well below this deal value — indicates that the buyer sees platform optionality, not just a single asset. This is a premium that reflects scarcity value in a market where differentiated mechanisms command outsized economics.

BridgeBio's $105M upfront from Novartis is the deal that should interest mid-cap biotech founders the most. It demonstrates that you don't need a $1B upfront to execute a meaningful other licensing 2026 transaction. A $105M upfront, likely with significant milestones and royalties, represents a structure where both parties share risk appropriately. BridgeBio has consistently positioned its pipeline at the intersection of genetic medicine and novel pharmacology — and Novartis is paying for that positioning.

The Amgen-BeiGene deal, with undisclosed terms, is worth watching. These two companies have a complex relationship history, and any new collaboration in non-traditional modalities could signal Amgen's strategic direction as it navigates its own LOE exposure.

What This Means for BD Teams Right Now

If you're a seller with a differentiated non-traditional asset, this is the most favorable market in a decade. The data is unequivocal: demand has outpaced supply by an order of magnitude. Upfront payments are elevated, total deal values are stretching into the high single-digit billions, and competition for assets is driving multi-party auction dynamics. If you have a platform technology, a novel delivery mechanism, or an asset that doesn't fit neatly into the antibody/small molecule/cell therapy taxonomy, your leverage is at peak. Use it.

For buyers, the window of advantage is closing fast. The jump from 7 to 96 deals means the market has already repriced. Waiting another two quarters will cost you — both in valuation premiums and in competitive positioning. The smart move is to identify assets before they enter formal processes. Proprietary deal flow matters more than ever. Structure creatively: consider co-development rights, opt-in milestones, and territorial splits that let you control economics without absorbing all the upfront risk. Use Solidus to pressure-test your term sheets against the current market.

Deal structures are shifting. The CSPC-AstraZeneca deal shows that massive upfronts ($1.2B) are back on the table for the right asset — but so are milestone-heavy structures like BridgeBio-Novartis ($105M upfront). The bifurcation is real: platform-level deals command platform-level upfronts, while single-asset licenses are being structured with more backend loading. BD teams should calibrate their offers based on whether they're acquiring a platform or a product. The market punishes misclassification.

The 1271% surge in other deal activity isn't a bubble — it's a correction. The industry systematically undervalued non-traditional modalities for years. The market is catching up.

Benchmark your deal against current market rates — whether you're structuring an upfront, negotiating milestones, or setting royalty tiers. Run your terms through the Ambrosia calculator to see where you stand relative to the 96 deals closed this period.